|
1) Bartsch G, Horninger W, Klocker H, et al. Prostate cancer mortality after introduction of prostate-specific antigen mass screening in the Federal State of Tyrol, Austria. Urology. 2001; 58: 417-24
|
|
|
|
2) Oberaigner W, Horninger W, Klocker H, et al. Reduction of prostate cancer mortality in Tyrol, Austria, after introduction of prostate-specific antigen testing. Am J Epidemiol. 2006; 164: 376-84
|
|
|
|
|
|
3) Bartsch G, Horninger W, Klocker H, et al. Tyrol prostate cancer demonstration project: early detection, treatment, outcome, incidence and mortality. BJU Int. 2008; 101: 809-16
|
|
|
|
|
|
4) Bouchardy C, Fioretta G, Rapiti E, et al. Recent trends in prostate cancer mortality show a continuous decrease in several countries. Int J Cancer. 2008; 123, 421-29
|
|
|
|
|
|
5) Schroder FH, Hugosson J, Roobol MJ, et al. Screening and prostate-cancer moratlity in a randomized European study. N Engl J Med. 2009; 360; 1320-8
|
|
|
|
|
|
6) Draisma G, Boer R, Otto SJ, et al. Lead times and overdetection due to prostate specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst. 2003; 95: 868-78
|
|
|
|
|
|
7) Steyerberg EW, Roobol MJ, Kattan MW, et al. Prediction of indolent prostate cancer: validation and updating of a prognostic nomogram. J Urol. 2007; 177: 107-12
|
|
|
|
|
|
8) Khatami A, Aus G, Damber JE, et al. PSA doubling time predicts the outcome after active surveillance in screening- detected prostate cancer: results from the European Randomized Study of Screening for Prostate Cancer, Sweden section. Int J Cancer. 2007; 120: 170-4
|
|
|
|
|
|
9) Roemeling S, Roobol MJ, Kattan MW, et al. Nomogram use for the prediction of indolent prostate cancer: impact on screen-detected population. Cancer. 2007; 110: 2218-21
|
|
|
|
|
|
10) Andriole GL, Crawford D, Brubb III RL, et al. Mortality results from a randomized prostate- cancer screening trial. N Engl J Med. 2009; 360: 1310-9
|
|
|
|
|
|
11) Screening for prostate cnacer: U. S. Preventives Services Task Force recommendation statement. Ann Intren Med. 2008: 149: 185-91
|
|
|
|
|
|
12) Barry MJ. Editorial. Screening for prostate cancer-the controversy that refuses to die. N Engl J Med. 2009; 360; 1351-4
|
|
|
|
|
|
13) Correspondence: prostate-cancer screening. N Engl J Med. 2009; 361: 202-6
|
|
|
|
|
|
14) Ito K, et al. Impact of exposure rate of PSA-screening on clinical stage of prostate cancer in Japan. J Urol. 2006; 175(suppl): 477-8
|
|
|
|
|